TRCT
QNCX icon

Tower Research Capital (TRC)’s Quince Therapeutics QNCX Stock Holding History

Tower Research Capital (TRC)’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3K Buy
567
+523
+1,189% +$12K ﹤0.01% 3987
2026
Q1 		$886 Sell
44
-31
-41% -$6.22K ﹤0.01% 4760
2025
Q4 		$50K Buy
75
+67
+838% +$33.7K ﹤0.01% 2412
2025
Q3 		$2.62K Buy
+8
New +$2.66K ﹤0.01% 4607
2025
Q1 		– Sell
-8
Closed -$3.17K – 5673
2024
Q4 		$3.17K Sell
8
-20
-71% -$6.01K ﹤0.01% 4695
2024
Q3 		$4.31K Sell
28
-20
-42% -$2.87K ﹤0.01% 4592
2024
Q2 		$7.21K Buy
48
+12
+33% +$2.17K ﹤0.01% 4484
2024
Q1 		$7.71K Buy
36
+2
+6% +$497 ﹤0.01% 4158
2023
Q4 		$7.09K Buy
+34
New +$6.81K ﹤0.01% 4660
2023
Q2 		– Hold
0
– – – 6299
2023
Q1 		– Hold
0
– – – 6192
2022
Q4 		– Sell
-41
Closed -$11K – 6275
2022
Q3 		$11K Buy
41
+19
+86% +$7.24K ﹤0.01% 4457
2022
Q2 		$9K Buy
22
+5
+29% +$3.53K ﹤0.01% 4578
2022
Q1 		$21K Sell
17
-14
-45% -$19.1K ﹤0.01% 3492
2021
Q4 		$79K Buy
31
+19
+158% +$116K ﹤0.01% 2394
2021
Q3 		$229K Sell
12
-10
-45% -$159K 0.01% 1690
2021
Q2 		$229K Buy
22
+8
+57% +$67.1K 0.01% 1817
2021
Q1 		$103K Sell
14
-11
-44% -$79.2K ﹤0.01% 2564
2020
Q4 		$138K Sell
25
-47
-65% -$416K ﹤0.01% 2052
2020
Q3 		$718K Buy
72
+60
+500% +$546K 0.01% 1297
2020
Q2 		$113K Buy
12
+10
+500% +$91.6K ﹤0.01% 2350
2020
Q1 		$15K Buy
+2
New +$19.7K ﹤0.01% 1843
2019
Q3 		– Sell
-2
Closed -$16K – 4443
2019
Q2 		$16K Buy
+2
New +$11.9K ﹤0.01% 2304

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s QNCX Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Quince Therapeutics (QNCX) stake by 1,189% in Q2 2026, buying an estimated $12K and bringing the position to 567 shares worth $10.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3987.

Tower Research Capital (TRC) first reported a position in QNCX in Q2 2019 and has held it in 21 quarters since. The position peaked at $718K in Q3 2020. 26 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Tower Research Capital (TRC) held 567 shares of Quince Therapeutics worth $10.3K as of Q2 2026.
  • Tower Research Capital (TRC) bought 523 Quince Therapeutics shares in Q2 2026, an estimated $12K.
  • Quince Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3987 holding.
  • Tower Research Capital (TRC) first reported a position in Quince Therapeutics in Q2 2019 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s Quince Therapeutics position peaked at $718K in Q3 2020.
  • 26 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.